glp 1 for mash Beyond glucagon-like peptide-1: The promise of polyagonists in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis—A systematic review of randomized trials Semaglutide Shows Major Promise for

Danuglipron made it further to Phase IIb, but Pfizer ended the entire program in April 2025 after a single asymptomatic case of potential drug-induced liver injury and dropped its third oral candidate a few months later

A., Norton, L

Sun exposure, smoking, and stress can reverse the effects

In both patient populations with pre-existing cardiovascular disease, DPP-4 inhibitors are recommended as one possible third-line therapy besides SGLT-2 inhibitors, thiazolidinediones, or insulin, when therapeutic goals are not met with the previous dual combination

This lab-created compound interacts with melanocortin receptors, supporting melanin pathway research and pigmentation response studies

Front Plant Sci 11:615942